评论：类风湿关节炎中，类风湿因子阳性而非抗环瓜氨酸肽抗体阳性、较低的残疾程度以及较少的抗 TNF 药物治疗失败与对利妥昔单抗的反应相关。 - Suppr | 超能文献

Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

作者信息

Belmonte Serrano Miguel A, Pincus Theodore

出版信息

Rheumatology (Oxford). 2010 Sep;49(9):1795-6; author reply 1796-7. doi: 10.1093/rheumatology/keq141. Epub 2010 May 19.

DOI:10.1093/rheumatology/keq141

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.评论：类风湿关节炎中，类风湿因子阳性而非抗环瓜氨酸肽抗体阳性、较低的残疾程度以及较少的抗 TNF 药物治疗失败与对利妥昔单抗的反应相关。

Rheumatology (Oxford). 2010 Sep;49(9):1795-6; author reply 1796-7. doi: 10.1093/rheumatology/keq141. Epub 2010 May 19.

2

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.类风湿因子阳性而非抗 CCP 阳性、较低的残疾程度和较少使用抗 TNF 药物失败与类风湿关节炎对利妥昔单抗的反应相关。

Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29.

3

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.利妥昔单抗治疗类风湿关节炎自身抗体阳性患者和 TNF 拮抗剂治疗失败患者的最高临床疗效：来自 10 个欧洲登记处的汇总数据。

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

4

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.生物抗风湿药物治疗常规改善病情抗风湿药或抗肿瘤坏死因子药物治疗反应不佳的类风湿关节炎患者的疗效的间接比较：一项荟萃分析。

Ann Rheum Dis. 2011 Feb;70(2):266-71. doi: 10.1136/ard.2010.132134. Epub 2010 Nov 19.

5

Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.抗环瓜氨酸化蛋白抗体作为类风湿关节炎患者抗肿瘤坏死因子-α治疗反应的预测指标。

J Rheumatol. 2006 Mar;33(3):497-500.

6

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.对接受抗 TNF 药物或传统 DMARDs 治疗应答不足的活动期类风湿关节炎患者用利妥昔单抗治疗应答的预测因子。

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):991-7. Epub 2011 Dec 22.

7

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.在类风湿关节炎中，英夫利昔单抗治疗可调节类风湿因子，但不调节抗环瓜氨酸肽抗体。

Ann Rheum Dis. 2005 Feb;64(2):299-302. doi: 10.1136/ard.2004.023523. Epub 2004 May 27.

8

[Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].[利妥昔单抗用于波兰对抗肿瘤坏死因子治疗难治的类风湿性关节炎]

Pol Merkur Lekarski. 2010 Dec;29(174):365-8.

9

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].类风湿因子阳性而非抗环瓜氨酸肽抗体阳性、较低的残疾程度以及较少的抗TNFα药物治疗失败与类风湿关节炎患者对利妥昔单抗的反应相关。

Reumatismo. 2009 Jul-Sep;61(3):182-6. doi: 10.4081/reumatismo.2009.182.

10

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.英国风湿病学会（BSR）和英国卫生与保健改善署（BHPR）关于利妥昔单抗在类风湿关节炎中应用的指南。

Rheumatology (Oxford). 2011 Dec;50(12):2311-3. doi: 10.1093/rheumatology/ker106a. Epub 2011 May 4.